UNSPSC 51161567: Eprozinol dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H30N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9AMI360PI, chemically known as 1-piperazinepropanol, 4-(2-methoxy-2-phenylethyl)-.alpha.-phenyl-, hydrochloride (1:2), but more generally known as eprozinol dihydrochloride, which bears US NIH Compound Identifier 161574.

European Medicines Agency schedules eprozinol dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06589MIG. Most nations, for tariff purposes, schedule eprozinol dihydrochloride under HS 29335995. SMILES: COC(CN1CCN(CC1)CCC(C2CCCCC2)O)C3CCCCC3.CL.CL.

UNSPSC 51161567 Eprozinol dihydrochloride, a Commodity code, covers the procurement of this specific pharmaceutical active ingredient and related generic multi-source pharmaceuticals and over-the-counter products by state and local government entities. State and local health systems, corrections departments, and human services agencies acquire these products through cooperative purchasing vehicles and direct contracts with manufacturers and authorized pharmaceutical wholesalers to supply clinical and institutional facilities. The buying pattern reflects demand for cost-controlled generic pharmaceuticals meeting FDA compliance and cGMP certification requirements, with vendors typically required to maintain relationships with established pharmaceutical distributors and demonstrate pricing flexibility across multiple formats (flat pricing, net pricing structures, and WAC-minus models).

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary visible recent buyer under this code. MMCAP issued an RFP on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions, with proposals due March 26, 2026. The solicitation required vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendors expected to be live by July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), with secondary factors including fixed pricing compliance, EDI capability, and administrative fee structure. Vendors must maintain workers' compensation and commercial general liability insurance of $5 million per occurrence, network security liability of $2 million, and professional liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation for reporting delays, missed onboarding timelines, or improper class-of-trade denials.